AAIC 2025 Abstract
Real‐World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy
Study in peopleInterventions
Abstract
Background: Lecanemab‐irmb (LEQEMBI®) is indicated for the treatment of patients with Alzheimer’s disease (AD) in the mild cognitive impairment or mild dementia stage.
